Inhibition of TMAO synthesizing enzyme, flavin-containing monooxygenase 3 (FMO3), with 3,30 -diindolylmethane reduces PERK Activation and Insulin resistance in vivo suggesting a potential route of the therapeutic intervention for metabolic syndrome. Here, FMO3 is linked to metabolic syndrome.